NovImmune ^Company

Novimmune is partnering with Tiziana which said March 11 that it will expedite development of TZLS-501 with Novimmune. Companies entered into a worldwide license in 2017. Tiziana notes that excessive production of IL-6 is a key driver of chronic inflammation, believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness. China’s National Health Commission has recommended the use of anti-IL6-R monoclonal antibodies to treat inflammation and elevated cytokine levels (cytokine storm) in COVID-19 patients.